Hartono J L, Koh T, Lee G H, Tan P S, Muthiah M, Aw M M, Madhavan K, Kow A, Lim K B
Yong Yoo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.
Department of Pharmacy, National University Health System, Singapore; National University Centre for Organ Transplantation, National University Health System, Singapore.
Transplant Proc. 2017 Jul-Aug;49(6):1419-1424. doi: 10.1016/j.transproceed.2017.02.049.
Adherence to immunosuppressive medications has been shown to affect post-transplant outcomes. We aimed to determine the level of adherence to immunosuppressive therapy in liver transplant (LT) recipients and to elucidate factors associated with it, as well as patient preferences on the dosing schedule.
LT recipients were recruited during transplant clinic follow-up. A validated Morisky 8-item questionnaire was completed by patients to assess their adherence to immunosuppressive therapy. Adherence was determined by the sum of the responses to the questionnaire. Low, medium, and high adherence were defined by a Morisky score of >2, 1 to 2, and 0, respectively. Data on the patient's socio-economic and clinical background, dosing schedule of immunosuppressant medications, and patient preferences were included in the questionnaire.
A total of 107 LT recipients were approached and 75 completed the questionnaire. The majority of patients (48/74, 64.9%) preferred a once-daily medication regimen. The proportion of high adherence was 24/75 (32.0%), medium adherence was 51/75 (42.7%), and low adherence was 19/75 (25.3%). Multivariate analysis showed younger age and post-transplant duration >5 years as independent predictors for low adherence. Among low-adherence patients, 16/19 (84.2%) patients were on a twice-daily regimen, and, of these, 14/16 (87.5%) preferred their medications to be reduced to once daily.
A significant proportion (68%) of LT recipients had low to moderate adherence to medications, with younger age and longer post-transplant duration of >5 years as independent predictors. Early identification of at-risk patients is essential to allow implementation of measures to improve adherence. Simplifying medication regimens to once daily is a potential way to improve adherence.
已证明免疫抑制药物的依从性会影响移植后的结局。我们旨在确定肝移植(LT)受者免疫抑制治疗的依从水平,阐明与之相关的因素以及患者对给药方案的偏好。
在移植门诊随访期间招募LT受者。患者完成一份经过验证的8项Morisky问卷,以评估他们对免疫抑制治疗的依从性。依从性通过问卷回答的总和来确定。低、中、高依从性分别定义为Morisky评分为>2、1至2和0。问卷中包括患者的社会经济和临床背景、免疫抑制药物的给药方案以及患者偏好的数据。
共接触了107名LT受者,75名完成了问卷。大多数患者(48/74,64.9%)更喜欢每日一次的给药方案。高依从性的比例为24/75(32.0%),中等依从性为51/75(42.7%),低依从性为19/75(25.3%)。多因素分析显示年龄较小和移植后时间>5年是低依从性的独立预测因素。在低依从性患者中,16/19(84.2%)患者采用每日两次的给药方案,其中14/16(87.5%)患者希望将药物减少至每日一次。
相当比例(68%)的LT受者对药物的依从性低至中等,年龄较小和移植后时间>5年是独立预测因素。早期识别高危患者对于采取措施提高依从性至关重要。将给药方案简化为每日一次是提高依从性的一种潜在方法。